This is a snippet of the transcript, sign up to read more.
This also gives Vitrolife a major advantage because no one else has this amount of data. With AI and big data, it's growing every day. They are collecting data every day from these EmbryoScopes installed globally. So no matter how people would come now and start doing something similar, there's a huge leap where Vitrolife is in front.
This is a snippet of the transcript, sign up to read more.
For Vitrolife, who is making the media, the dishes, and the EmbryoScope, you have all the right people and competencies involved in optimizing this. Some companies have some of these things, but not all of them. If you add software developers who have done this for many years, it's hard to catch up.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.